A Phase Ib Safety lead-in, Followed by Phase II Trial of ADG106 in Combination With Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer

NCT05275777 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

66

Enrollment

OTHER

Sponsor class

Conditions

HER2-negative Breast Cancer
Advanced Solid Tumor

Interventions

DRUG: ADG106
DRUG: Doxorubicin
DRUG: Cyclophosphamide
DRUG: Paclitaxel

Sponsor

National University Hospital, Singapore

Collaborators

[object Object]